US 10966977
Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
granted A61KA61K31/4155A61K31/416
Quick answer
US patent 10966977 (Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders) held by TG Therapeutics, Inc. expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TG Therapeutics, Inc.
- Grant date
- Tue Apr 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61K, A61K31/4155, A61K31/416, A61K31/4985, A61K31/506